Coherus BioSciences, Inc.  announced that the United States Food and Drug Administration (“FDA”) approved YUSIMRY™ , formerly CHS-1420, a Humira® (adalimumab) biosimilar product. YUSIMRY is indicated for plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, Crohn’s disease, and ulcerative colitis. “We are excited that Coherus has received FDA approval for YUSIMRY, our second approved

Telix Pharmaceuticals Limited, a global biopharmaceutical company focused on the development of diagnostic and therapeutic products based on molecularly targeted radiation , today announces that the United States Food and Drug Administration  has approved Telix’s lead prostate cancer imaging product, Illuccix®. Illuccix is a kit for the preparation of gallium-68 (68Ga) gozetotide (also known as PSMA-11) injection, a radioactive diagnostic agent indicated for positron

In partnership with Gulf Drug, Versius has been acquired by hospitals across the UAE, where it is being used in a rapidly increasing number of surgeries in both public and private hospitals including at the Saudi German Hospital, Al Zahra Hospital, and American Hospital Dubai. The UAE, amongst other countries across the Middle East, has made considerable and rapid advances to adopt surgical robotics into clinical practice, and is seeing significant benefits by enabling more patients to receiv

Boyd Corporation, a world-leading innovator of technologies in engineered materials and thermal management, announced the acquisition of MBK Tape Solutions. MBK specializes in the manufacturing and development of innovative and complex multi-layered adhesive products that bond, mount, monitor and protect for stick to skin applications in the highly regulated medical industry. The acquisition strengthens Boyd’s medical material science capability across advanced wound care, transdermal p

Acadia Healthcare Company, Inc. announced that it has formed a joint venture with Fairview Health Services, one of Minnesota’s leading health systems. Through this partnership, Fairview and Acadia plan to design and construct a new inpatient mental health and addiction facility in the Twin Cities’ East Metro. The joint venture will bring together the two organizations’ expertise and resources to address an identified need for behavioral health services in the region.

MDoloris Medical Systems, leader in the field of objective analgesia/nociception monitoring during anesthesia and in intensive care, and Mindray, a global leader in developing and providing advanced medical devices and solutions, announce today the CE Mark and upcoming launch of the Mdoloris ANI-MR module. The ANI-MR module is a solution developed by MDoloris for Mindray for integration into the BeneVision N Series patient monitoring devices, making the ANI parameter available to al

Blue Cross and Blue Shield of Minnesota (Blue Cross) today announced that it has funded investments in technology and practice support resources for Community Memorial Hospital (CMH) in Cloquet, Minnesota, allowing new training capabilities to optimize labor and delivery care for patients throughout the state.' The Operative Experience Labor and Delivery Suite, which was recently installed at CMH, provides a life-like simulation for all types of obstetric care, from routine proc

Svelte Medical Systems received U.S. Food and Drug Administration (FDA) approval to commercialize the SLENDER IDS® fixed-wire and DIRECT RX® rapid-exchange drug-eluting stent (DES) systems for the treatment of coronary artery disease in the U.S. SLENDER IDS® and DIRECT RX®, incorporating the same specialized stent, bioresorbable drug coating and balloon technologies, achieved 1.5% clinically-driven Target Lesion Revascularization (TLR) at 1 year in the OPTIMIZE Investigational

Acadia Healthcare Company, Inc. announced that it has formed a joint venture with SCL Health, one of Colorado’s premier healthcare systems. The new partnership will build a new 144-bed facility in the Denver area. The new freestanding behavioral health hospital will expand comprehensive inpatient and outpatient services to address the growing need for accessible, high-quality behavioral health services in the Denver metro area. The facility is expected to open in the middle of 2023.

Paragon 28, Inc. announced today that it has received a supplemental approval order from the U.S. Food and Drug Administration ("FDA") for the Patient Specific Talus Spacer. The supplemental approval order allows the Patient Specific Talus Spacer to be additively manufactured in titanium alloy with a titanium nitride coating. The Patient Specific Talus Spacer was first approved on February 17, 2021, by the FDA under a Humanitarian Device Exemption for treatment of avascula